Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients (vol 5, pg 312, 2017)

被引：3
|
作者：
de Velasco, G.
Je, Y.
Bosse, D.
Awad, M. M.
Ott, P. A.
Moreira, R. B.
Schutz, F.
Bellmunt, J.
Sonpavde, G. P.
Hodi, F. S.
Choueiri, T. K.
机构：
来源：
CANCER IMMUNOLOGY RESEARCH | 2018年 / 6卷 / 04期
关键词：
D O I：
10.1158/2326-6066.CIR-18-0078
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：498 / 499
页数：2
相关论文
共 50 条
  • [41] Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer: meta-analysis
    Shen, Xian
    Zhao, Bin
    BMJ-BRITISH MEDICAL JOURNAL, 2018, 362
  • [42] Correlation between immune-related adverse events and the efficacy of PD-1/PD-L1 inhibitors in the treatment of non-small cell lung cancer: systematic review and meta-analysis
    Qian Zhang
    Wei Wang
    Qi Yuan
    Li Li
    Yu-Chao Wang
    Chuan-Zhen Chi
    Chun-Hua Xu
    Cancer Chemotherapy and Pharmacology, 2022, 89 : 1 - 9
  • [43] Correlation between immune-related adverse events and the efficacy of PD-1/PD-L1 inhibitors in the treatment of non-small cell lung cancer: systematic review and meta-analysis
    Zhang, Qian
    Wang, Wei
    Yuan, Qi
    Li, Li
    Wang, Yu-Chao
    Chi, Chuan-Zhen
    Xu, Chun-Hua
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2022, 89 (01) : 1 - 9
  • [44] Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials A Systematic Review and Meta-analysis
    Wang, Yucai
    Zhou, Shouhao
    Yang, Fang
    Qi, Xinyue
    Wang, Xin
    Guan, Xiaoxiang
    Shen, Chan
    Duma, Narjust
    Aguilera, Jesus Vera
    Chintakuntlawar, Ashish
    Price, Katharine A.
    Molina, Julian R.
    Pagliaro, Lance C.
    Halfdanarson, Thorvardur R.
    Grothey, Axel
    Markovic, Svetomir N.
    Nowakowski, Grzegorz S.
    Ansel, Stephen M.
    Wang, Michael L.
    JAMA ONCOLOGY, 2019, 5 (07) : 1008 - 1019
  • [45] Cardiovascular adverse events and immune-related adverse events associated with PD-1/PD-L1 inhibitors for head and neck squamous cell carcinoma (HNSCC)
    Abulizi, Adila
    Yan, Guangpeng
    Xu, Qian
    Muhetaer, Reyihanguli
    Wu, Shihan
    Abudukelimu, Kudelaiti
    Chen, Xi
    Liu, Chengjiang
    Li, Jun
    SCIENTIFIC REPORTS, 2024, 14 (01):
  • [46] Prognostic Significance of the Severity of Immune-Related Adverse Events in Advanced Cancer Patients Treated with PD-1/PD-L1 Inhibitors: A Real-World Data Analysis
    Song, Su Jeong
    Song, Yun-Kyoung
    Jang, Mihwa
    Shin, Eunjeong
    Suh, Sung Yun
    Cho, Yoon Sook
    Lee, Ju-Yeun
    Oh, Jung Mi
    TARGETED ONCOLOGY, 2023, 18 (01) : 147 - 158
  • [47] The efficacy and safety of combination of PD-1 and CTLA-4 inhibitors: a meta-analysis
    Wu, Kongju
    Yi, Ming
    Qin, Shuang
    Chu, Qian
    Zheng, Xinhua
    Wu, Kongming
    EXPERIMENTAL HEMATOLOGY & ONCOLOGY, 2019, 8 (01)
  • [48] The efficacy and safety of combination of PD-1 and CTLA-4 inhibitors: a meta-analysis
    Kongju Wu
    Ming Yi
    Shuang Qin
    Qian Chu
    Xinhua Zheng
    Kongming Wu
    Experimental Hematology & Oncology, 8
  • [49] Prognostic Significance of the Severity of Immune-Related Adverse Events in Advanced Cancer Patients Treated with PD-1/PD-L1 Inhibitors: A Real-World Data Analysis
    Su Jeong Song
    Yun-Kyoung Song
    Mihwa Jang
    Eunjeong Shin
    Sung Yun Suh
    Yoon Sook Cho
    Ju-Yeun Lee
    Jung Mi Oh
    Targeted Oncology, 2023, 18 : 147 - 158
  • [50] New and Worsening Long-term Immune-Related Adverse Events with PD-1/PD-L1 Pathway Agents in Patients with Cancer
    Hall, Kevin H.
    Liu, Yuan
    Jiang, Chen
    Harvey, R. Donald
    PHARMACOTHERAPY, 2020, 40 (02): : 133 - 141
12345